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ENHANCEMENT OF ANTIBIOTIC
EFFICACY

certain embodiments, a method comprises administering to
a microbe the antibiotic with a synthetic amphiphile. In
certain embodiments, the synthetic amphiphile is a com
pound comprising one or more polar head groups in which

CROSS - REFERENCE TO RELATED
APPLICATIONS

This application is a U.S. National Phase application of
PCT /US2015 /034550, filed on Jun . 5 , 2015 , which claims

the benefit of U.S. Provisional Application No. 62/ 008,956
filed Jun . 6 , 2014 both of which are hereby incorporated by

reference in their entireties.

STATEMENT OF FEDERALLY SPONSORED
RESEARCH

This invention was made with Government support under
CHE 1307324 awarded by the National Science Foundation.
The Government has certain rights in the invention .

5 each polar head group comprises at least three oxygen and
hydrocarbon residues as the nonpolar elements. In certain
embodiments, the synthetic amphiphile is a lariat ether or a
hydraphile. In certain embodiments, the antibiotic and syn
thetic amphiphile are administered to the microbe such as by
10 contacting the microbe in culture or in solution or by
applying the antibiotic and synthetic amphiphile to a mate
15

rial, such as the surface of a material, in or on which the
microbe resides . In certain embodiments, the method
increases the antimicrobial activity of the antibiotic by about
2 - fold to about 40 - fold .
In certain embodiments, the synthetic amphiphile is a
lariat ether. In certain embodiments, the synthetic amphi

phile is a lariat ether and the lariat ether comprises a
diaza - 18 - crown - 6 macrocycle and two linear alkyl chains
Certain synthetic amphiphiles are known to exhibit tox 20 ranging in length from 1 to 20 carbon atoms, or from 1 to 22
icity to microbes such as Gram negative Escherichia coli , carbon atoms . In certain embodiments, the synthetic amphi
Gram positive Bacillus subtilis, and the yeast Saccharomy phile is a lariat ether and the lariat ether comprises a
ces cerevisiae . The minimum inhibitory concentrations diaza - 15 - crown - 5 macrocycle and two linear alkyl chains
( MICs ) of such synthetic amphiphiles against the various ranging in length from 1 to 20 carbon atoms, or from 1 to 22
microbes depend on the microbe per se and on the structure 25 carbon atoms.In certain embodiments, the synthetic amphi
of the synthetic amphiphile .
phile is a lariat ether and the lariat ether is N ,N '-di-n -octyl
Combination drugs such as amoxicillin and clavulanic 4,13 -diaza - 18 -crown - 6 . In certain embodiments, the syn
acid, sold as AUGMENTIN® , and piperacillin and tazo
thetic amphiphile is a lariat ether and the lariat ether is
bactam , sold as ZOSYN®, are effective antimicrobials. N , N -di - n -decyl- 4,13 - diaza - 18 - crown -6 . In certain embodi
Certain amphiphilic calixarene molecules have been pre
ments , the synthetic amphiphile is a lariat ether and the lariat
pared with integral antibiotic elements, but these comprise 30 ether is N ,N -di-n -undecyî-4,13 -diaza- 18 -crown -6 . In cer
prodrugs rather than combination therapies as described in tain embodiments , the synthetic amphiphile is a lariat ether
Bioorganic and Medicinal Chemistry 2012 , 20 , 2035-2041 . and the lariat ether is N ,N -di-n -dodecyl-4,13-diaza -18
There still remains a need to identify composition and crown - 6 . In certain embodiments, the synthetic amphiphile
methods to enhance antimicrobial activity of current anti is a lariat ether and the lariat ether is N ,N - di-n -tetradecyl
microbial agents and to combat increasing microbe resis 35 4,13 -diaza - 18 - crown - 6 . In certain embodiments, the syn
tance to antibiotics.
thetic amphiphile is a lariat ether and the lariat ether does not
comprise an adamantyl group .
SUMMARY
In certain embodiments, the synthetic amphiphile is a
hydraphile. In certain embodiments , the synthetic amphi
Disclosed herein are various embodiments of a method of phile is a hydraphile and the hydraphile comprises the
enhancing the antimicrobial activity of an antibiotic . In structure of Formula 4 :
BACKGROUND

Formula 4

- ( CH2)n - N

N- (CH2)n - N

wherein n is 6. In certain embodiments , the synthetic amphi
phile is a hydraphile and the hydraphile comprises the
structure of Formula 4 :

Formula 4

N- (CH2)n

N

- (CH2) n

N
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3

4

wherein n is 8. In certain embodiments, the synthetic amphi
phile is a hydraphile and the hydraphile comprises the

is administered to a concentration of about 0.1 uM to about
400 uM and the synthetic amphiphile is administered to a

structure of Formula 4 :

concentration of about 0.1 uM to about 400 UM .
Formula 4

N- (CH2)n - N

N

N

- ( CH2) n - N

20

In certain embodiments, the antibiotic is an antibiotic
selected from the group consisting of kanamycin, tobramy
cin , erythromycin , rifampicin , and tetracycline. In certain

wherein n is 10. In certain embodiments , the synthetic
amphiphile is a hydraphile and the hydraphile comprises the
structure of Formula 2 :

N

embodiments, the antibiotic is an antibiotic selected from

the group consisting of erythromycin , rifampicin , and tet

Formula 2

R2.

spacer

-spacer

o

25

racycline. In certain embodiments, the antibiotic is kanamy
cin . In certain embodiments, the antibiotic is tobramycin. In
certain embodiments, the antibiotic is erythromycin . In
certain embodiments, the antibiotic is rifampicin. In certain
embodiments, the antibiotic is tetracycline.
In certain embodiments, the microbe is E. coli , the anti

biotic is selected from the group consisting of rifampicin ,

wherein the macrocycles ( open circles ) are 4,10 -diaza -15
crown
-5, the spacers are n -dodecylene, and the side chains 30 tetracycline
, kanamycin, and erythromycin, and the syn
thetic amphiphile is N , N - di - n -octyl -4,13 -diaza - 18 - crown - 6

(R2) are n -dodecyl. The diamond (middle between spacers )

represents a polar structural element. In certain embodi
ments, the polar structural element is a macrocycle . Com

lariat ether or N , N - di - n -undecyl - 4,13 -diaza - 18 - crown - 6
lariat ether. In certain embodiments, the microbe is a tetra

but
rather a triethyleneoxy unit or an amide- containing
module.

microbial infection . Such methods comprise administering

cycline resistant strain of E. coli , the antibiotic is tetracy
pounds
3
and
7
as
shown
in
FIG
.
10
are
representative
35
hydraphiles in which the polar element is not a macrocycle cline , and the synthetic amphiphile is a hydraphile.
In certain embodiments, the microbe is a bacterium . In

Certain embodiments provide for methods of treating a

to a subject suffering from the microbial infection an effec
tive amount of a combination of an antibiotic and a synthetic

certain embodiments, the microbe is a bacterium in the 40 amphiphile as described herein .

family Enterobacteriaceae, in the family Bacillaceae , or in

BRIEF DESCRIPTION OF DRAWINGS
the family Pseudomonadaceae. In certain embodiments, the
bacterium is Escherichia coli ( E. coli) . In certain embodi
ments, the microbe is a bacterium that is resistant to the
FIG . 1 illustrates chemical structures of N ,N -di- n - octyl
antibiotic . In certain embodiments, the bacterium is an 45 4,13 - diaza - 18 - crown - 6 and N ,N ’-di -n - undecyl-4,13 -diaza

18 - crown- 6 , which are exemplified in the present disclosure .
FIG . 2 illustrates chemical structures of five antibiotics
in the present disclosure .
understood to mean any compound that either inhibits or thatFIGare. 3exemplified
is a graphical representation of lariat ether toxicity
completely arrests or prevents microbial growth or kills the 50 to HEK 293
cells .
microbe .
FIG . 4 is a graphical comparison of N , N '-dialkyl-4,13
In certain embodiments , the antibiotic, the synthetic diaza
- 18 - crown - 6 lariat ether toxicity ( LD50 ) to E. coli and
amphiphile, or both the antibiotic and the synthetic amphi to HEK
293 cells .
phile are administered at a concentration below their mini
FIG
.
5
is a synthetic scheme for the preparation of
mum inhibitory concentrations. In certain embodiments, the 55 N , N '-di - n - octyl
- 4,13 -diaza - 18 - crown -6 .
antibiotic is administered at a concentration below its mini
FIG
.
6
is
a
graph
showing the relationship between the
mum inhibitory concentration . In certain embodiments, the concentrations of synthetic
and antibiotic
synthetic amphiphile is administered at a concentration required to inhibit the growth ofamphiphile
DH50 E. coli treated with
below its minimum inhibitory concentration . In certain Cg lariat ether and tetracycline.
embodiments, both the antibiotic and the synthetic amphi- 60 FIG . 7 shows the minimum inhibitory concentration
phile are administered at concentrations below their mini (MIC ) for DH5a E. coli treated with Cg lariat ether and
mum inhibitory concentrations when determined in the rifampicin when treated with various concentrations of
absence of the second additive. In certain embodiments, the amphiphile and antibiotic .
antibiotic resistant E. coli .
In the present context, antibacterial and antimicrobial are

antibiotic is administered to a concentration of about 0.1 uM
FIG . 8 shows the minimum inhibitory concentration
to about 400 uM . In certain embodiments, the synthetic 65 (MIC ) for DH5a E. coli treated with C11 lariat ether and
amphiphile is administered to a concentration of about 0.1 tetracycline when treated with various concentrations of
UM to about 400 ?M . In certain embodiments, the antibiotic synthetic amphiphile and antibiotic .

US 10,791,740 B2
5

FIG . 9 shows the minimum inhibitory concentration

6

Hydraphiles are synthetic amphiphiles known in the art

( MIC ) for DH5a E. coli treated with Chi lariat ether and
rifampicin when treated with various concentrations of
synthetic amphiphile and antibiotic .

such as described in Chemical Communications 2000 , 1-9 .
Hydraphiles are typically composed of three macrocyclic

FIG . 11 shows the chemical structure of TRITON X - 100 .

spacer chains can contain 1-30 carbon atoms and can be

rings, separated by organic spacer elements, and terminated
FIG . 10 shows seven representative examples of chemical 5 by various side arms. In certain embodiments, the side arm
structures of hydraphiles and hydraphile -like compounds. can be hydrogen attached to a nitrogen heteroatom . The

FIG . 12 shows the correspondence between membrane saturated or unsaturated , linear or branched, including aro
thickness and hydraphile spacer chain length as determined matic and heteroaromatic . The side arms can be linear or
10 branched alkyl, unsaturated alkyl, aralkyl, aryl, or heteroaryl
by the percentage of ions released from vesicles.
FIG . 13 shows illustrative examples of lariat ether struc
and the spacer chains can contain heteroatoms such as
oxygen , nitrogen , and/ or sulfur. Hydraphiles have also been
tures that have been prepared .
prepared that have two (e.g. , 3 , 7 ) and four (e.g. , 5 ) mac
DETAILED DESCRIPTION
rocyclic rings that function as pore -formers in bilayer mem
15 branes as shown in FIG . 10 .
It is to be noted that the term “ a” or “ an ” entity refers to
Amphiphiles are compounds that have both polar and
one or more of that entity ; for example, " an antibiotic” is non - polar elements . A synthetic amphiphile as understood
understood to represent one or more antibiotics . As such , the herein is a compound that contains at least one polar element
terms “ a” ( or “ an ” ). “ one or more , ” and “ at least one” can be or " head group ” and at least one nonpolar element or “ tail.”
used interchangeably herein .
20 TRITON X - 100 , shown in FIG . 11 , is one representative
Unless defined otherwise , all technical and scientific example . The compound numbered 7 in FIG . 10 is another
terms used herein have the same meaning as commonly representative example and has two polar macrocycles and
understood by one of ordinary skill in the art to which this a triethyleneoxy group that can also serve as a polar head
disclosure is related .
group .
Units, prefixes, and symbols are denoted in their Système 25 An example of a synthetic amphiphile is the detergent
International de Unites ( SI ) accepted form . Numeric ranges sold as TRITON X - 100 (FIG . 11 ) in which the hydrocarbon
are inclusive of the numbers defining the range. The head residue is nonpolar and the oligoethylene glycol portion is
ings provided herein are not limitations of the various polar. Certain embodiments are directed to synthetic amphi
aspects of the disclosure, which can be had by reference to philes such as , but not limited to , N , N -di -n -undecyl -4,13
the specification as a whole .
30 diaza - 18 - crown - 6 . In this compound , the 18 -membered
It has been discovered that the combination of certain macrocyclic ring possesses six heteroatoms ( four oxygens

synthetic amphiphiles with a range of antimicrobial agents,

such as antibiotics, shows unexpectedly enhanced efficacy,
increased activity, etc., of the antimicrobial agents against a

and two nitrogens) that render the cyclic structure polar. The

two 11 -carbon chains attached to the two macrocyclic ring
nitrogen atoms are hydrophobic and nonpolar and comprise

range of organisms, including in some cases those microbes 35 the synthetic amphiphile’s nonpolar elements . FIG . 1 is an
that are resistant to a particular antimicrobial agent. It has
further been discovered that certain hydraphiles that are too )

illustrative example showing the chemical structures of
N , N -bis ( n -octyl ) -4,13 -diaza - 18 - crown - 6 and N ,N '-bis (n
short to form ion - conducting channels surprisingly and undecyl) -4,13 -diaza - 18 -crown - 6 . It is understood, however,
unexpectedly also enhanced antimicrobial activity. It was that the methods described herein are not limited to the
also discovered that organisms that are resistant to certain 40 synthetic amphiphiles illustrated in FIG . 1 .
antimicrobial agents succumb to that antimicrobial agent
Certain aspects are drawn to a method for increasing or
when the antimicrobial agent and one or more synthetic enhancing the antimicrobial activity of an antimicrobial
amphiphiles, such as those described herein , is co -adminis agent. As used herein , the “ antimicrobial activity ” of an
tered with the antimicrobial agent.
antimicrobial agent is defined as the property of a substance
Lariat ethers are compounds known in the art as cation 45 to inhibit the growth and reproduction of a microbial organ
complexing agents such as described in U.S. Pat . Nos . ism or to kill it . Common terms generally applied to bacteria
4,436,664 , 4,474,963 , 4,597,903 , and 4,687,844 . Lariat are bacteriostatic ( stops growth ) and bactericidal ( kills bac

ethers contain a macrocyclic ring and one or more sidearms teria ). Depending on the concentrations applied, microbial
as described herein . A macrocycle is a ring compound growth can be slowed or stopped in comparison to concur
comprising at least 9 -members, but more typically 12 or 50 rent experiments conducted in the absence of an antimicro

more atoms connected together. Macrocyclic rings at least as
large as 60 atoms are also known in the art. Lariat ethers are
characterized by a macrocyclic ring having from 12-48
members and containing heteroatoms including , but not
limited to , oxygen , nitrogen and sulfur. Lariat ethers possess 55

one or more side arms or side chains attached to the

bial agent. Depending on the concentrations applied , addi
tional microbe death can occur in comparison to concurrent
experiments conducted in the absence of an antimicrobial
agent. The results of minimum inhibitory concentration
(MIC ) evaluations and growth curves are presented herein
and the conditions are specified. The MIC is the lowest

macrocyclic ring. The attachment of the side chains can be concentration of any agent having antimicrobial activity that
at carbon , nitrogen , or sulfur or any combination thereof inhibits the growth of a microorganism as judged by visual
within the ring. Heteroatoms such as oxygen , nitrogen , and inspection . MIC can be determined by inoculating media
sulfur can also be present in the side arms. The side arms can 60 with the organism and adding the antimicrobial agent diluted
be linear or branched alkyl, unsaturated alkyl, aralkyl, aryl, successively in half . After an appropriate incubation time ,
or heteroaryl, and heteroatoms such as oxygen, nitrogen , the MIC is evaluated by inspection as the transition between
and / or sulfur can be present in or attached to the aralkyl,

two successive 2 - fold dilutions in which the one concen

aryl, or heteroaryl portions of the side chains . Lariat ethers trated sample is clear and growth is apparent in the 2 - fold
are known to be amphiphiles as described in Advances in 65 less concentrated sample . Reference herein to increasing or
Bio - organic Frontiers ; H. Dugas , Springer Verlag: Berlin . enhancing activity, efficacy, potency, and the like are used
interchangeably to mean that when the synthetic amphiphile
1990 ; Vol. 1 ; pp 116-141 .
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is present, the ability of the antimicrobial agent to inhibit the
growth of or to kill an organism will be manifested at a
concentration lower than would be required to achieve the
same results in the absence of said synthetic amphiphile. In
certain embodiments, the method increases the antimicrobial
activity of the antibiotic by : about 2 - fold to about 40 - fold ; by
about 5 - fold to about 40 - fold; by about 10 - fold to about
40 - fold ; by about 15 - fold to about 40 - fold ; by about 20 - fold
to about 40 - fold ; by about 25 - fold to about 40 - fold ; by about
30 - fold to about 40 - fold , by about 35 - fold to about 40 - fold ;
or by about 40 - fold . In certain embodiments, the method
increases the antimicrobial activity of the antibiotic ; by
about 2 - fold to about 48 - fold ; by about 5 - fold to about
48 - fold ; by about 10 - fold to about 48 - fold ; by about 15 - fold
to about 48 -fold ; by about 20 - fold to about 48 - fold ; by about
25 - fold to about 48 - fold ; by about 30 - fold to about 48 - fold ;
by about 35 - fold to about 48 - fold ; by about 40 - fold to about
48 - fold ; or by about 48 - fold . In certain embodiments, the
method increases the antimicrobial activity of the antibiotic ;
by about 2 - fold to about 50 - fold ; by about 5 - fold to about
50 - fold ; by about 10 - told to about 50 - fold ; by about 15 - fold
to about 50 - fold ; by about 20 - fold to about 50 - fold ; by about
25 - fold to about 50 - fold ; by about 30 - fold to about 50 - fold ;
by about 35 - fold to about 50 - fold ; by about 40 - fold to about
50 - fold ; by about 50 - fold , or greater than about 50 - fold .
In certain embodiments , the antimicrobial agent is an
antibiotic . The structures of five illustrative antibiotics are
shown in FIG . 2 ( i.e. , kanamycin , tobramycin , erythromy
cin , rifampicin , and tetracycline ). It is understood that the
methods described herein are not limited to the antibiotics
illustrated in FIG . 2. Other antibiotics are exemplified herein
and numerous other antibiotics, too numerous to list , are
contemplated . For example, the following is a brief list of
some compounds that are within the scope of the disclosure:

8

about 0.1 uM to about 100 uM ;
about 0.1 uM to about 50 uM ;
about 0.1 uM to about 25 uM ;
about 0.1 uM to about 10 uM ; or
5 about 0.1 uM to about 1.0 uM .
In certain embodiments, the antibiotic is administered to
a concentration of:
about 0.001 uM to about 400 uM ;
about 0.01 uM to about 400 uM ;
about 0.1 uM to about 400 uM ;
10 about
1.0 uM to about 400 uM ;
15

20

25

30

about 10 uM to about 400 uM ;
about 100 uM to about 400 uM ;
about 200 uM to about 400 uM ;
about 300 uM to about 400 uM ;
about 0.001 uM to about 300 uM ;
about 0.01 uM to about 300 uM ;
about 0.1 uM to about 300 uM ;

about 1.0 uM to about 300 uM ;
about 10 uM to about 300 uM ;
about 100 uM to about 300 uM ;
about 200 uM to about 300 uM ;
about 0.001 uM to about 200 uM ;
about 0.01 uM to about 200 uM ;
about 0.1 uM to about 200 uM ;
about 1.0 uM to about 200 uM ;
about 10 uM to about 200 uM ;
about 100 uM to about 200 uM ;
about 0.001 uM to about 100 UM ;
about 0.01 uM to about 100 uM ;
about 0.1 uM to about 100 uM ;
about 1.0 uM to about 100 uM ;
about 10 uM to about 100 uM ; or
about 50 uM to about 100 uM .
Certain aspects are drawn to a method for increasing or

Carbapenems such as Imipenem , Meropenem , Ertapenem , 35 enhancing the antimicrobial activity of an antimicrobial

Doripenem , and Biapenem ; penicillins, cephalosporins ( Ce
foxitin ), glycopeptides ( vancomycin ), macrolides (azithro
mycin , clarithromycin ), quinolones ( ciprolloxacin , naldixic
acid ), sulfamides ( sulfadiazine ), isoniazid, and streptomy

agent by administering the antimicrobial agent in combina
tion with a synthetic amphiphile. In certain embodiments ,
the synthetic amphiphile that is capable of increasing or
enhancing antimicrobial activity is a lariat ether and / or a

cin . In certain embodiments, the antibiotic is administered to 40 hydraphile. In certain embodiments, a synthetic amphiphile
is capable of reversing the resistance of a microbe to an
antimicrobial agent. In certain embodiments, the synthetic
about 0.001 uM to about 400 uM ;
amphiphile that is capable of reversing the resistance of a
about 0.001 uM to about 300 uM ;

a concentration of:

about 0.001 uM to about 200 uM ;
microbe to an antimicrobial agent is a lariat ether and / or a
45 hydraphile. In certain embodiments, the synthetic amphi
about 0.001 uM to about 100 uM ;
phile is administered to a concentration of:
about 0.001 uM to about 50 uM ;
about 0.001 uM to about 400 uM ;
about 0.001 uM to about 25 uM ;
about 0.001 uM to about 300 uM ;
about 0.001 uM to about 10 uM ;
about 0.001 uM to about 200 uM ;
about 0.001 uM to about 1 uM ;
50
about 0.001 uM to about 0.1 uM ; or
about 0.001 uM to about 100 uM ;
about 0.001 uM to about 50 uM ;
about 0.001 uM to about 0.01 uM .
In certain embodiments , the antibiotic is administered to
about 0.001 uM to about 25 uM ;
a concentration of:
about 000.1 uM to about 10 uM ;
about 0.01 uM to about 400 uM ;
about 0.001 uM to about 1 uM ;
55
about 0.001 uM to about 0.1 uM ; or
about 0.01 uM to about 300 uM ;
about 0.001 uM to about 0.01 uM .
about 0.01 uM to about 200 uM ;
In certain embodiments, the synthetic amphiphile is
about 0.01 uM to about 100 uM ;
administered to a concentration of :
about 0.01 uM to about 50 uM ;
about 0.01 uM to about 400 uM ;
about 0.01 uM to about 25 uM ;
60
about 0.01 uM to about 10 uM ;
about 0.01 uM to about 300 uM ;
about 0.01 uM to about 200 uM ;
about 0.01 uM to about 1 uM ; or
about 0.01 uM to about 100 uM ;
about 0.01 uM to about 0.1 uM .
In certain embodiments, the antibiotic is administered to
about 0.01 uM to about 50 uM ;
a concentration of:
about 0.01 uM to about 25 uM ;
65
about 0.01 uM to about 10 uM ;
about 0.1 uM to about 400 uM ;
about 0.01 uM to about 1 uM ; or
about 0.1 uM to about 300 uM ;
about 0.1 uM to about 200 uM ;
about 0.01 uM to about 0.1 uM .
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In certain embodiments , the synthetic amphiphile is

compounds having spacer chains shorter than eight linear
atoms can also be classified as short - chained hydraphiles.
The graph of FIG . 12 also shows that in the thickest DEPC

administered to a concentration of :

about 0.1 uM to about 400 uM ;
about 0.1 uM to about 300 uM ;
membranes, C10 benzyl hydraphile is nearly inactive . Thus,
about 0.1 uM to about 200 uM ;
5 short - chained hydraphiles are those that fail to transport
about 0.1 uM to about 100 uM ;
cations by pore formation in the context of the organism's
about 0.1 uM to about 50 uM ;
membrane structure. It is known from the Journal of the
about 0.1 uM to about 25 uM ;
American Chemical Society 2002 , 124 , 9022-3 , that
about 0.1 uM to about 10 uM ; or
hydraphiles are toxic to E. coli in appropriate concentra
10
about 0.1 uM to about 1.0 uM .
tions . Thus, C12 benzyl hydraphile killed E. coli but Cg
In certain embodiments , the synthetic amphiphile is benzyl
hydraphile did not.
administered to a concentration of.
about 0.001 uM to about 400 uM ;
about 0.01 uM to about 400 uM ;
about 0.1 uM to about 400 uM ;

about 1.0 uM to about 400 UM ;

about 10 uM to about 400 uM ;
about 100 uM to about 400 uM ;
about 200 uM to about 400 uM ;
about 300 uM to about 400 uM ;

about 0.001 uM to about 300 uM ;
about 0.01 uM to about 300 uM ;
about 0.1 uM to about 300 uM ;
about 1.0 uM to about 300 uM ;
about 10 uM to about 300 uM ;
about 100 uM to about 300 uM ;
about 200 uM to about 300 uM ;
about 0.001 uM to about 200 uM ;
about 0.01 uM to about 200 uM ;
about 0.1 uM to about 200 uM ;
about 1.0 uM to about 200 uM ;
about 10 uM to about 200 uM ;
about 100 UM to about 200 uM ;
about 0.001 uM to about 100 uM ;
about 0.01 uM to about 100 uM ;
about 0.1 uM to about 100 uM ;
about 1.0 uM to about 100 uM ;
about 10 uM to about 100 uM ; or
about 50 uM to about 100 uM .

As used herein , a short - chained hydraphile comprises
spacerchains of such a length that they do not span the lipid
15 bilayer of a particular membrane to which the short- chained
hydraphiles are contacted and therefore do not exhibit the
property of cation transport by pore formation . In certain
embodiments, a short - chained hydraphile has spacer chains
of ten or less linear atoms. In certain embodiments, a
20 short -chained hydraphile has spacer chains of eight or less
linear atoms . In certain embodiments, a short - chained
hydraphile has spacer chains of six or less linear atoms .

A general formula for lariat ethers is shown as Formula 1 .
25

Formula 1

Q
30
R

35

In Formula 1 , the circle represents a macrocyclic ring,
which can be composed of heteroatoms such as O , N , and / or
S. The ring sizes can range from about 12 members to about
48 members. The side arms (R) can be saturated or unsatu

It is understood that in certain embodiments, the antibiotic 40 rated alkyl , saturated or unsaturated aralkyl, aryl or substi
and the synthetic amphiphile can be administered together to tuted aryl including heteroaromatic groups. The side arms
can possess heteroatoms such as oxygen , nitrogen, and / or
the respective concentrations disclosed herein .
In certain embodiments, a short -chain hydraphile is used sulfur. Heteroatoms can also be present in groups appended

to increase or enhance the potency or antimicrobial activity to the aryl or heteroaryl residues. In certain of any of the
of an antimicrobial agent. In certain embodiments, a short- 45 embodiments disclosed herein , a lariat ether does not com
chain hydraphile is used to reverse the resistance of a prise an adamantyl group . In certain of any of the embodi
microbe to an antimicrobial agent. Short - chained
ments disclosed herein , an adamantyl group is not incorpo
hydraphiles have spacer chains of such a length that they do rated as a terminal residue in a side chain or the side chains
not span the lipid bilayer and therefore do not exhibit the of a lariat ether of the embodiments .
property of cation transport by pore formation . The length 50 A general formula for hydraphiles is shown as Formula 2 .
dependence was demonstrated in Chemical Communica
tions 1998 , 2477-2478 . However, it is well known in the art
that the membranes of cells have many different components

and thicknesses. It was demonstrated in the Journal of the
American Chemical Society 2005 , 126 , 636-642 , that the 55
ability of hydraphiles to transport cations depended on the
correspondence between membrane thickness and

hydraphile spacer chain length . Thus, liposomes were
formed from three different phospholipids: 1,2 -dimyristo
leoyl -sn - glycero -3-phosphocholine (DMPC, shorter fatty 60
acid chains, thinner membranes), 1,2 -dioleoyl- sn - glycero - 3
phosphocholine (DOPC ) , and 1,2 -dierucoyl-sn - glycero -3
phosphocholine (DEPC , longest fatty acid chains, thickest
membranes ). The graph of FIG . 12 shows that C , benzyl
hydraphile failed to transport irrespective of whether it was 65
present in DMPC , DOPC , or DEPC membranes . The Cg
benzyl hydraphile is a short- chained hydraphile and those

Formula 2

R2

spacer

spacer

O
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The spacers ( also referred to as “ spacer chains ” ) can range

Lariat ethers similar to Formula 3 but having 12 -mem

from 1-30 atoms and can be linear or branched , and can be bered macrocyclic rings are also provided for.
The side arms (R ) of lariat ethers can be linear or
saturated or unsaturated . The size of the macrocyclic rings
can range from about 12 members to about 48 members . The branched alkyl, unsaturated alkyl, aralkyl, or aryl, or het
side arms ( R2 ) can be linear or branched, saturated or 5 eroaryl. When the value of “ n ” in the structure of FIG . 3 is
unsaturated alkyl, saturated or unsaturated aralkyl, aryl or 1 , the macrocyclic ring is 4,13 - diaza - 18 - crown - 6 . When R1

is saturated alkyl, the side chains can be methyl, ethyl,

substituted aryl including heteroaromatic groups. The side

arms can possess heteroatoms such as oxygen , nitrogen ,

and / or sulfur. Heteroatoms can also be present in groups

appended to the aryl or heteroaryl residues. The diamond

(middle between spacers ) represents a polar structural ele
ment. In certain embodiments, the polar structural element is

10

normal alkyl from n - propyl to n - eiscosanyl ( also called
n - icosanyl) or branched chain isomers thereof. The corre
sponding branched chain isomers and / or unsaturated deriva
tives are also contemplated as are various ring sizes and
heteroatom compositions including , but not limited to , O , N ,

a macrocycle. Compounds 3 and 7 as shown in FIG . 10 are

and S. Non - limiting illustrative examples of lariat ethers

structure shown in Formula 3 , where n has values from

atoms , or from 1 to 22 carbon atoms; N ,N -di-n -octyl-4,13

representative hydraphiles in which the polar element is not 15 include : diaza - 18 - crown - 6 macrocycle with two linear alkyl
a macrocycle but rather a triethyleneoxy unit or an amide
chains ranging in length from 1 to 20 carbon atoms, or from
containing module.
1 to 22 carbon atoms; diaza - 15 -crown - 5 macrocycle with
A more specific illustrative example of a lariat ether is the two linear alkyl chains ranging in length from 1 to 20 carbon

about 0 to about 16 , or from about 4 to about 16 , and R ' is 20 diaza - 18 -crown - 6 ; N , N -di- n -decyl -4,13 -diaza -18 - crown - 6 ;
described below .
N.N '-di- n - undecyl-4,13 -diaza - 18 - crown - 6 ; N ,N -di-n -dode
cyl -4,13 - diaza - 18 -crown - 6 ; and N ,N - di- n -tetradecyl- 4,13

Formula 3

R — N

diaza - 18 - crown - 6 . A representative example of a lariat ether
25 having a more complex structure is the compound shown as
6 in FIG . 10. Compound 6 in FIG . 10 can also be described
as a bolaamphiphile .

Formula 2 above shows a generalized structure for the
30 aforementioned side arms and the term “ spacer” designates
the linkage units that covalently connect the macrocyclic

compounds known as hydraphiles. In Formula 2. R2 are the

NR

rings.
A more specific illustrative example of a hydraphile is the
structure shown in Formula 4 , where n is the number of
methylene groups from 1-30 .
Formula 4

N- (CH2)n

- (CH2)n

Some non - limiting illustrative examples of hydraphiles

include : the structure of Formula 4 :

Formula 4

N

N

- (CH2)n

N

N

- (CH2)n -N
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wherein n is 6 ; the structure of Formula 4 :
Formula 4

N

N- (CH2)n

N

- (CH2 ) -N

wherein n is 8 ; the structure of Formula 4 :
Formula 4

- (CH2) n

- (CH2)n

wherein n is 10 , 12 , 14 , or 16 ; and the structure of Formula 30 and suffering from a microbial infection . In certain embodi
2:
ments, a combination of an antibiotic and a synthetic amphi
phile as disclosed herein is administered in an effective
amount. An “ effective amount " is that amount, the admin

Formula 2

R2

spacer

spacer

R2

wherein the macrocycles ( open circles ) are 4,10 -diaza - 15
crown - 5 , the spacers are n- dodecylene , and the side chains

(R2) are n-dodecyl , and the diamond is 4,10 -diaza-15

crown - 5 . Represented another way, in certain embodiments,
the structure can be R2 — X — S - Y - S - X_R ?: wherein X
( the macrocycles ) can be 4,10 -diaza - 15 - crown - 5 . S (spac
ers ) can be n -dodecylene, R2 ( side chains ) can be n - dodecyl ,
and Y (polar structural element) can be 4,10 -diaza - 15
crown - 5 .
Certain aspects are drawn to the administration of synthetic amphiphiles with antimicrobial agents. In certain
embodiments, the synthetic amphiphile is a lariat ether or a
hydraphile. A combination of the antimicrobial agent and the
synthetic amphiphile can be administered by any route ,
protocol, means , etc. , appropriate for its administration and
embodiments are not limited to any particular route , proto
col , means . etc. of administration . For example, the antibi
otic and synthetic amphiphile can be administered to the
microbe such as by contacting the microbe in culture or in
solution or by applying the antibiotic and synthetic amphiphile to a material, such as the surface of a material, in or on
which the microbe resides. Administration can be to a
subject having a microbial infection and such administration
to the subject results in administration to the microbe. For
example , the subject can be a plant or an animal. In certain
embodiments, the subject can be a mammal. In certain
embodiments, the mammal subject can be a human having

istration of which to a subject (also referred to as a patient),
35 either in a single dose or as part of a series , is effective for
treatment. For example, and effective amount can be an
amount that is sufficient to reduce the severity of a microbial
infection ( or one or more symptoms thereof), ameliorate one
or more symptoms of an infection, prevent the advancement
40 of the infection, cause regression of infection , or enhance or
improve the therapeutic effect ( s) of another therapy. In some
embodiments, the effective amount cannot be specified in
advance and can be determined by a caregiver, for example,
by a physician or other healthcare provider, using various
45 means, for example, dose titration . Appropriate therapeuti
cally effective amounts can also be determined by routine
experimentation using , for example, animal models .
In certain embodiments , the antimicrobial agent and the
synthetic amphiphile can be administered orally, intrave
50 nously, intramuscularly, intraperitoneally, by ointment,
cream or any other topical or surface application or surface
coating. The antimicrobial agent and synthetic amphiphile
can be administered in a single treatment or administered
multiple times such as on a schedule or in a series over a
55 period of time . The antimicrobial agent and the synthetic
amphiphile can be administered at the same time or practi
cally at the same time , such as immediate sequential admin
istration . In certain embodiments, the antimicrobial agent
and the synthetic amphiphile are pre -combined with each
60 other into a composition comprising a combination of anti
microbial agent and synthetic amphiphile. Thus, the antimi
crobial could be covalently attached to the hydraphile or
lariat ether through an ester linkage which could be cleaved
by endogenous esterase or amidase enzymes. In certain
65 embodiments, the antimicrobial agent can be administered
first followed by administration of the synthetic amphiphile.
In certain embodiments, the synthetic amphiphile can be

US 10,791,740 B2
15

16

administered first followed by administration of the antimi

oxygen , nitrogen , and / or sulfur. Heteroatoms can also be

crobial agent. The antimicrobial agent is considered to be present in groups appended to the aryl or heteroaryl residues .
administered with the synthetic amphiphile so long as both
compositions are simultaneously contacted with a microbe
Formula 5
even if not simultaneously applied, such as simultaneous in 5
a culture with a microbe, simultaneously on a surface with
a microbe, or simultaneously in a subject being treated . In
certain embodiments, the simultaneous presence of both the
antimicrobial agent and the synthetic amphiphile act
together to enhance antimicrobial activity. In certain 10
R2
R2
embodiments, the simultaneous presence of both the anti
microbial agent and the synthetic amphiphile reverse the

resistance of a microbe to the anti -microbial agent.
In certain embodiments , the synthetic amphiphile, the
antimicrobial agent, or both the synthetic amphiphile and the 15
antimicrobial agent are administered at concentrations

below their minimum inhibitory concentration (MIC ) val

ues . When certain antimicrobial agents and lariat ethers or
certain antimicrobial agents and hydraphiles, one or more at
concentrations below their minimum inhibitory concentra- 20
tions , are co - administered to bacteria in the family Entero
bacteriaceae ( such as but not limited to E. coli) , to bacteria
in the family Bacillaceae ( such as but not limited to B.
subtilis) , and to bacteria in the family Pseudomonadaceae
( such as but not limited to Pseudomonas aeruginosa ), the 25
efficacy of the antibiotic /synthetic amphiphile combination
is enhanced by as much as about 30 - fold , or by as much as

about 48 - fold , or greater compared to the activity of either
individual component. Efficacious results have been

observed in the Gram negative bacterium Escherichia coli as
contemplated along with known strains of other Gram
negative bacteria such as Pseudomonas aeruginosa . Appli
cation to Gram positive bacteria including but not limited to
B. subtilis is also contemplated . Other bacteria and
microbes , including but not limited to Candida albicans,
Trichophyton rubrum , Aspergillus, blastomyces, dermatiti
des, Cryptococcus neoformans, Mycobacterium , Klebsiella ,
Eniterococcus, Staphylococcus, and primitive eukaryotes
such as yeast , for example Saccharomyces cerevisiae, and
fungi, are also contemplated herein .
It has also been discovered that synthetic amphiphiles
such as , but not limited to , lariat ethers and hydraphiles can
be administered with an antimicrobial agent, such as an
antibiotic, to organisms resistant to the antimicrobial agent,
such that the resistant organism becomes susceptible to the
antimicrobial agent. This is referred to herein as reversing
the resistance of a microbe to an antimicrobial agent such as
reversing the resistance of a bacterium to an antibiotic . As
used herein , antibiotic “ resistance ” or the assertion that an
organism is “ resistant ” to antibiotics means that some part or
all of the organism in question does not respond to the
antibiotic either by having its growth inhibited or being
killed . For example, the tetracycline resistant E. coli
reported herein were obtained from a commercial supplier
and it was found that their MIC was ~ 900 uM . This
compares with the MIC of 12 uM reported in Table 5 for
tetracycline against E. coli . This means that the tetracycline
resistant E. coli requires a ~ 75 - fold greater concentration of
antibiotic to inhibit growth .
In certain embodiments, the synthetic amphiphile can be
a bis (amide) compound having the chemical structure of
Formula 5. The size of the macrocyclic ring can range from
about 12 members to about 48 members. The side arms can
be saturated or unsaturated alkyl, saturated or unsaturated
aralkyl, aryl or substituted aryl including heteroaromatic
groups. The side arms can possess heteroatoms such as
the DH5a or K - 12 strain . Other strains of E. coli are

30

35

The synthesis of compounds such as N , N '-bis ( n -octyl ) -4 ,

13 - diaza - 18 - crown - 6 and N , N '-bis (n -undecyl) -4,13 -diaza
18 - crown- 6 can readily be accomplished by methods known
in the art. An example is to treat 4,13 -diaza - 18 - crown - 6 with
an alkyl acid chloride such as n - octanoyl chloride , which in
turn can be prepared from octanoic acid and a chlorinating
agent such as thionyl chloride ( SOC12 ) or oxalyl chloride
(CICOCOCI ) . The result of this reaction is a di- tertiary
amide that can be reduced, for example, with lithium alu
minum hydride ( LiAlH_) or borane ( BH3.THF ) . A typical
reaction is illustrated in FIG . 5. It is meant to exemplify the
synthetic approach and process but not to be in any way
limiting.
In certain embodiments, lariat ether compounds can have
ring sizes that range from 12 members to 48 members. The
side chain substituents shown as R1 or R2 in Formulas 2
and /or 3 , can be normal or branched alkyl having from 1-20
carbon atoms , or from 1-22 carbon atoms . These substitu
ents can also be unsaturated, multiply unsaturated, cis and / or
trans unsaturated , aralkyl, aromatic, or heteroaromatic. The
side arms can possess heteroatoms such as oxygen , nitrogen,
and /or sulfur. Heteroatoms can also be present in groups
appended to the aryl or heteroaryl residues. Eighteen illus

40 trative
structures that have been prepared are shown in FIG .
13 .
45

50

55

60

65

In certain embodiments, the microbe is E. coli , the anti
biotic is selected from the group consisting of rifampicin ,
tetracycline, kanamycin , and erythromycin , and the syn
thetic amphiphile is N , N -di - n -octyl -4,13 -diaza - 18 -crown - 6
or N , N -di- n -undecyl -4,13 -diaza - 18 -crown - 6 . In certain
embodiments, the microbe is E. coli , the antibiotic is rifam
picin , and the synthetic amphiphile is N ,N -di-n -octyl-4,13
diaza - 18 - crown - 6 . In certain embodiments , the microbe is E.
coli , the antibiotic is tetracycline, and the synthetic amphi
phile is N , N '- di - n -octyl -4,13 - diaza - 18 -crown -6. In certain
embodiments, the microbe is E. coli , the antibiotic is rifam
picin , and the synthetic amphiphile is N , N- di- n- undecyl - 4 ,
13 - diaza - 18 - crown - 6 lariat ether. In certain embodiments,
the microbe is E. coli , the antibiotics tetracycline, and the
synthetic amphiphile is N ,N -di- n -undecyl-4,13 - diaza - 18
crown - 6 lariat ether. In certain embodiments, the microbe is
E. coli , the antibiotic is kanamycin, and the synthetic amphi
phile is N , N °-di- n -undecyl-4,13 -diaza - 18 - crown - 6. In cer
tain embodiments , the microbe is E. coli , the antibiotic is
erythromycin , and the synthetic amphiphile is N ,N -di-n
undecyl -4,13 - diaza -18 -crown - 6 .
In certain embodiments, the microbe is a tetracycline
resistant strain of E. coli , the antibiotic is tetracycline, and
the synthetic amphiphile is a hydraphile . In certain embodi
ments, the microbe is a tetracycline resistant strain of E. coli ,
the antibiotic is tetracycline, and the synthetic amphiphile is
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benzyl Cg hydraphile. In certain embodiments, the microbe
Table 3 shows the effect of combining rifampicin or
is a tetracycline resistant strain of E. coli , the antibiotic is tetracycline with N ,N '-bis (n -undecyl )-4,13 -diaza - 18
tetracycline
hydraphile. , and the synthetic amphiphile is benzyl C14 crown - 6 and then exposing the E. coli to the combination .
The following disclosed embodiments are merely repre- 5
TABLE 3
sentative. Thus, specific structural, functional, and proce
dural details disclosed in the following examples are not to
Combination of C11 lariat ethers and
antibiotics against DH5a E. coli
be interpreted as limiting .
EXAMPLES

10 Side
Chain

Among the organisms studied are several strains of the
C11
bacterium E. coli . These include, but are not limited to , nn-- C11
DH5a , JM109 , K - 12 , and tetracycline - resistant E. coli , the n- C11
latter being an E. coli strain possessing the tet - A efflux 15 n -C1

pump . Experiments were conducted to determine the MIC
values for the synthetic amphiphiles known as lariat ethers
according to the procedures described in Antimicrobial
M07 - A9 : Methods for Dilution Antimicrobial Susceptibility
Tests for Bacteria that Grow Aerobically; Clinical and
Laboratory Standards Institute, 2012 ; Vol. 32 , 67 pp . MIC
values so determined for several lariat ethers and for several

n -C11
n -C11
n -C11

n -C11

20

MIC Used

MIC Used

(UM) (UM) Antibiotic
24
18 rifampicin
24
16 rifampicin
24
12 rifampicin

(UM ) (UM ) DMSO

24
24
24
24
24

8 rifampicin
18 tetracycline
16 tetracycline

12 tetracycline
4 tetracycline

60
60

60
60
12
12
12
12

3

vol- %
0.4
0.4
0.4

6

6

15
1.5

0.25
1
3

Fold
Enhance
ment
20
10

0.4

10
4

0.4
0.4
0.4
0.4

8
48
12
4

Table 4 shows the effect on the K - 12 strain of E. coli by
combining various N ,N - disubstituted - 4,13 - diaza - 18

crown - 6 lariat ethers having side arms possessing six to

antibiotics are shown in Table 1 .

twelve carbon atoms with either tetracycline or rifampicin .

TABLE 1

25

Minimum Inhibitory Concentrations for
Synthetic Amphiphiles and Antibiotics.
Antibiotic or R ?

TABLE 4
Combination of lariat ethers and antibiotics against K -12 E. coli

MIC (UM )

in Formula 3

E. coli

B. stubtilis

S. cerevisiae

n - octyl
n - decyl
n - undecyl
n - dodecyl
n -tetradecyl
n - hexadecyl
n - octadecyl
erythromycin
kanamycin
rifampicin
tetracycline
tobramycin

120

105
2.8

25
2.8
1.5
2.5
>300
> 300

11
24
> 300
> 300
> 300

9
2.5

> 300
> 300
> 300

>300
> 400

> 300

30
60
12
15

30

MIC Used

Amphiphile
Cg lariat ether

(UM ) (UM ) Antibiotic
300 64 Tetracycline

C10 lariat ether
C11 lariat ether
C12 lariat ether
35 Co lariat ether
Cg lariat ether
Cg lariat ether
C10 lariat ether

12 1.5 Tetracycline
24 6 Tetracycline
> 512 16 Tetracycline
> 512 250 Rifampicin
300 64 Rifampicin
300 32 Rifampicin
12 6 Rifampicin

Cu lariat ether

24

6 Rifampicin

40

Fold
MIC Used Enhance

(UM ) ( UM )
2.5
6
6
6
20
20
20
20
20

3
2.5
3
10
5
10
5
10

ment

NA

Previous studies of C12 lariat ether did not show toxicity
Table 2 shows the effect of combining rifampicin or subtilis and to S. cerevisiae at minimum inhibitory On n
tetracycline with N , N- bis ( n-octyl ) -4,13 - diaza - 18 - crown- 6 trations ( MICs ) of 2.5 uM . The MICs of Co. Cg . C1o . C11
and then exposing the E. coli to the combination . Note that 45 and C14 lariat ether to DH15a E. coli were determined to
DMSO is the standard abbreviation for dimethylsulfoxide. be >360 UM , >240 uM , 12 UM , 24 uM and >360 UM
respectively. Peak transport activity was observed for C10
TABLE 2
lariat ether, which was the most toxic compound in the MIC
study. Two - armed Cg and Cu lariat ethers have also been
Combination of Cg lariat ethers and
50 shown to enhance the efficacy of rifampicin and tetracycline
antibiotics against DH5a E. coli
in DH5a E. coli . Here we have performed toxicity studies of

to DH5a E. coli cells but the compound was lethal to B.

Fold

MIC

Chain

( UM) (UM ) Antibiotic

(UM) (UM ) DMSO

n - Cg

> 120
> 120
> 120
> 120
> 120
> 120
> 120
> 120

n - C8

n-Cg
n - Cg
n - Cg
n-Cg

n - Cg
n - C8
n-Cg

> 120

80 rifampicin
60 rifampicin
40 rifampicin

100 tetracycline
80 tetracycline
60 tetracycline

40 tetracycline
30 tetracycline
20 tetracycline

64
64

64
12
12

lariat ethers to human embryonic kidney HEK - 293 cells to

Used vol- % Enhance
ment

MIC Used

Side

3 + 1
3 + 1
3 +1

0.4
0.4

0.25
0.5

0.4

12
12
12

2
2
3

0.4
0.4
0.4
0.4
50.6

12

12

0.4

21
21
21
48
24
6
6
4

0

determine the selectivity of the lariat ethers between mam

malian and bacterial cells .
55

The toxicity of Co. Cg , C1o . C11 and C14 lariat ethers to

HEK - 293 cells was determined by using an MTT assay .
Results are presented in FIG . 3 , in graphical form for the
percent survival of HEK - 293 cells in the presence of various
concentrations of lariat ethers. The abscissa is a logarithmic
60 scale for the concentrations ranging from 1 uM to 1000 uM
( 1 mM ) used in the experiment. The ordinate represents

percent survival of HEK - 293 cells . For Cg and Cu lariat
ether, concentrations equivalent to half MIC to E. coli , i.e.
60 uM and 12 uM respectively, were also tested for toxicity

Table 2 also shows the effect of combining tetracycline
with N , N '-bis ( n -octyl ) -4,13 -diaza - 18 - crown -6 and then 65 to HEK - 293 cells .
exposing the E. coli to the combination . The MIC of
FIG . 3 shows the percent survival of HEK - 293 in the
presence of various concentrations of lariat ethers . The
tetracycline decreases in the presence of DMSO .

US 10,791,740 B2
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ordinate ranges from 0-100% and records the survival of
human embryonic kidney (HEK - 293 ) cells when exposed to
concentrations ( 1 uM to 1 mM ) of lariat ethers having linear
side arms ranging from six to fourteen carbon atoms .

having (CH2) : spacers did not exhibit toxicity to E.
coli , whereas the benzyl C , hydraphile having (CH2) 2
spacers killed the bacteria .

All previous studies , both biophysical and biological ,
As seen in FIG . 3 , with the increase in concentrations of 5 indicated that hydraphiles of the general type shown in
lariat ethers, the percent survival decreases. HEK - 293 cells Formula 4 would be inactive on their own or as adjuncts to
have 90% survival in the presence of 0.5 % DMSO . Hence , antimicrobial agents if their spacer chains [ ( CH2)n- ]
the ~ 90 % survival of HEK - 293 cells in the presence of 1 uM contained 8 or fewer methylene groups. It was unexpectedly
Cg and C11 lariat ethers is attributed to the toxicity of DMSO 10 discovered that the short hydraphile benzyl Cg significantly
(within experimental error as reflected in the error bars ) . C14
the potency of several antibiotics.
lariat ether is considered non- toxic even at 1 mM ( 1000 uM) enhanced
Studies
with a tetracycline -resistant strain of E. coli ,
because 45 % survival of HEK - 293 is observed .
specifically tetracycline -resistant JM109 , have shown that
Two commonly used abbreviations are LD50 and IC 50 lariat ethers produce significant enhancements of antimicro
The former is the concentration of an agent that comprises bial
potency. A JM109 strain that is highly resistant to the

ais lethal
dose to 50% of the organism under study. The latter 15 antibiotic tetracycline was studied in the presence of various
the concentration of agent that inhibits growth of 50% of

the organism under study. The data presented and graphed in
FIG . 4 represent the averaged (multiple replicates ) LD50
concentrations of Co. Cg , C10 , C12 , and C14 lariat ethers

lariat ethers at different concentrations. As shown by the data
in Table 6 , the antimicrobial resistance was reversed. Table
5 shows the results for the tetracycline - resistant JM109

against HEK -293 cells. It also shows the inhibitory concen- 20 strain of E. coli in the presence of lariat ethers.

tration (IC50 ) for each compound to DH5a E. coli cells . The
abscissa represents the number of ( CH2 ) groups in spacer
chains. The ordinate is logarithmic and reflects the concen
trations ( in uM) of the various lariat ethers used . The MIC
values of C and C14 lariat ethers are greater than 360 uM but 25
for the purpose of graphical presentation, the IC50 values are

TABLE 5
MIC values for synthetic amphiphiles or antimicrobials
against tetracycline resistant E. coli

Amphiphile

Antimicrobial

MIC ( UM )

considered at 180 uM . At 180 UM C4 , and C14 lariat ethers
are inactive against E. coli.
FIG . 4 shows the toxicity of various side chain length

Cg
hydraphile
C10 hydraphile

None

250 + 10
35 + 5

open circles ( dashed line ) represent the average LD50 to

Cg lariat ether

None
None

C12 lariat ether

None

None

Ampicillin

lariat ethers to HEK - 293 and DH5a E. coli . In FIG . 4 , the 30
HEK - 293 cells whereas the squares ( solid line) represent the

IC50 to E. coli . The IC50 for Cg lariat ether to E. coli ( 150
UM) is much higher than the LD50 to HEK - 293 (33 UM) . The

IC50 for C11 lariat ether to E. coli ( 12 uM) is lower than the 35
LD50 to HEK - 293 ( 22 UM) . The synergy experiments for Cg

and Cu lariat ethers were performed at 60 uM and 12 uM ,
respectively. In the presence of 60 um Ca lariat ether, 27 %

survival of HEK - 293 cells was observed . In the presence of

None
None
None

C12 hydraphile
C14 hydraphile
Co lariat ether

C10 lariat ether
Cu lariat ether

5 + 0.5
2 + 0.125
> 512
120
16
24
> 512
900 + 50
> 1000

None
None
Tetracycline

None

Studies with several strains of E. coli have shown that

lariat ethers produce significant enhancements of antimicro
bial potency. In particular, a study of tetracycline - resistant E.

12 ?M C . ,With
lariattheetherincrease
, 66% survival
HEKlength
-293 cells
was 40 coli showed that in the presence of lariat ethers, the antimi
observed
in side ofchain
of lariat
crobial resistance was reversed . Data are shown in Table 6
ethers, the IC50 to E. coli is observed to be lower than LD50 for treatment with lariat ethers and tetracycline of tetracy
to HEK - 293 . This data suggests that with an increase in side cline - resistant strains of E. coli .
chain length , the toxicity of lariat ether to HEK - 293 is lower
than that to E. coli . Similar to the toxicity trend in E. coli , 45
TABLE 6
C10 lariat ether had the highest toxicity to HEK - 293 .
Combination of lariat ether and tetracycline
Minimum inhibitory concentrations were determined
against tetracycline resistant E. coli
using protocols described above for various synthetic
amphiphiles and antimicrobials against DH5a , K - 12 , and
Fold
tetracycline-resistant strains of E. coli . The data are sum- 50
MIC Used Enhance
MIC Used
marized in Table 5. N , N -Dibenzyl -4,13 -diaza -18 -crown -6 is Amphiphile
(UM ) (UM ) Antibiotic
(UM ) ( UM ) ment
referred to in the table as dibenzyldiaza - 18 -crown - 6. The C. lariat ether > 512 192 Tetracycline 900 413
2
compounds referred to as C , benzyl hydraphile and C14 Cg lariat ether
10
120
80 Tetracycline 900 87
benzyl hydraphile have the structures shown in Formula 4 , Cg lariat ether
5
120
60 Tetracycline 900 175
120
4
40 Tetracycline 900 233
55 Cg lariat ether
in which “ n ” is 8 and 14 , respectively .
16
4
6 Tetracycline 900 225
Initial studies of hydraphile - enhanced antimicrobial activ C1o
C10 lariat
lariat ether
ether
16
16
9 Tetracycline 900 56
ity were conducted with three hydraphiles. These are illus C11 lariat ether
10
24
18 Tetracycline 900 87
trated in Formula 4 , in which “ n ” = 12 , 14 , and 16. In several
published studies , it was found that hydraphiles having

Cu lariat ether

Society 2002 , 124 , 9022-9023 . In this report, the hydraphile

crobial resistance was reversed . Data are shown in Table 7

C11 lariat ether

24
24
24
> 512

16
12
8
192

Tetracycline
Tetracycline
Tetracycline
Tetracycline

900
900
900
900

87
87
175
450

10
10
5
2

spacer chains [ -( CH2 )n ] in the 12-16 range were invari- 60 C12
C11 lariat
lariat ether
ether
ably the most active ion transporters. These results can be
found in the following articles : Chemical Communications
1998 , 2477-2478 and Journal of Supramolecular Chemistry
Studies with several strains of E. coli have shown that
2001 , 1 , 23-30 . It was discovered that hydraphiles that hydraphiles produce significant enhancements of antimicro
successfully formed ion channels in membranes also killed 65 bial potency. In particular, a study of tetracycline - resistant E.
E. coli , as reported in the Journal of the American Chemical coli showed that in the presence of hydraphiles, the antimi
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for treatment with hydraphiles and tetracycline of tetracy

1. Streak the E. coli ( DH5a or K - 12 MG 655 ) strain on L.B
agar plates. For tetracycline resistant E. coli use L.B.
agar + ampicillin plates ( 150 uM) .
2. Inoculate a 2 ml of L.B. Miller media with one colony of
bacteria and incubate overnight at 37 ° C. and 200 rpm .
For tetracycline resistant E. coli , use 128 uM ampicillin in

cline - resistant strains of E. coli .

TABLE 7
5

Combination of hydraphile and tetracycline
against tetracycline resistant E. coli

Amphiphile

Cg hydraphile
Cg hydraphile
C10 hydraphile
C10 hydraphile
C12 hydraphile
C12 hydraphile
C14 hydraphile
C14 hydraphile

L. B. Miller media .

MIC

Used

MIC Used

Fold
Enhance

(UM )

(UM) Antibiotic
125
Tetracycline

(UM ) (UM )

ment

250
250

35
35
5
5
2
2

62.5
17.5
8.75
2.5
1.25
1

Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline

0.5 Tetracycline

900
900
900
900
900

900
900
900

30
82
40
200
55
400
220
360

30
11
23
5
16
2

10

15

4
3

The synthetic amphiphile shown as Compound 6 in FIG .
tetracycline resistant strain . In the presence of tetracycline
and in the absence of a synthetic amphiphile, the MIC values
against K - 12 and the tetracycline resistant strain were 6 ?M
and 900 uM , respectively. For the K - 12 strain , addition of
Compound 6 in FIG . 10 at a concentration of approximately 25
half its MIC , in the presence of tetracycline, altered the MIC
of tetracycline from 6 uM to 2 uM . This is an approximately
three - fold increase in efficacy. For the tetracycline - resistant
strain , addition of compound 6 in FIG . 10 at a concentration
of approximately half its MIC , in the presence of tetracy 30
cline, altered the MIC of tetracycline from 900 uM to 150
UM . This is an approximately six -fold increase in efficacy .
Referring to FIGS. 6 through 9 which show plots of
antibiotic concentration as a function of lariat ether concen
tration for the antibiotics tetracycline and rifampicin with Cg
and Cum lariat ethers. FIG . 6 is a graph showing the rela 35
tionship between the concentrations of synthetic amphiphile
and antibiotic required to inhibit the growth of E. coli treated
with Cg lariat ether and tetracycline. FIG . 7 is a graph
showing the relationship between the concentrations of
synthetic amphiphile and antibiotic required to inhibit the 40
growth of E. coli treated with Cg lariat ether and rifampicin.
FIG . 8 is a graph showing the relationship between the
concentrations of synthetic amphiphile and antibiotic
required to inhibit the growth of for E. coli treated with Cu
lariat ether and tetracycline. FIG . 9 is a graph showing the 45
relationship between the concentrations of synthetic amphi
phile and antibiotic required to inhibit the growth of E. coli
treated with C11 lariat ether and rifampicin . Graphical rep
resentations are known to those in the art as a means to 50
assess whether a combination of drugs is additive or syner
gistic as described in Drug Synergism and Dose -Effect Data

10 was examined with two E. coli strains : K - 12 and the 20

Analysis; Chapman & Hall : Boca Raton , 2000 , 267 pp .

Example 1. N , N -Di - n -octyl -4,13 - diaza - 18 -crown - 6
This compound was prepared by methods known in the
art . 4,13 -Diaza - 18 - crown - 6 was acylated with octanoyl
chloride and the resulting diamide was reduced with
BHG.THF. Short path distillation afforded the lariat ether
( 63 % ) as a colorless oil (bp 181-190 ° C. , 0.04 torr ).
Example 2. Determination of Minimum Inhibitory

55

3. Prepare an excel file outlining the concentrations and
volumes of compound and L.B. Miller media required to

be added to each test tube . Note : The total volume of

media is 2000 uL in each test tube .
4. Prepare initial concentration of all the compounds
required .
5. Dilute from the initial concentration according to the

required concentration of the compound. Note : For com
pounds that are dissolved in DMSO , dilutions must be
made in a way that the volume of DMSO added to each
test tube is kept constant at 5 uL ( 0.25 % by volume). For
compounds that are dissolved in water, the volume of
water added to media is constant at 5 uL (0.25 % by
volume)

6. Add the appropriate volume of media to each test tube .
7. In a separate test tube, knock back E. coli to optical
density (A= 600 nm . O.D . ) =0.100 by adding 50 uL of E.
coli to 1950 uL of L.B. Miller media . Check O.D. every
30 minutes until the E. coli grows to O.D. =0.600 .
8. While the E. coli grows, add the appropriate volume of
compound to each test tube.

Vortex each test tube for 2-3 seconds .

9. Add 20 uL E. coli grown to O.D. =0.600 to each sample .
Note : Manage experiments so that E. coli is grown to
O.D. =0.600 before adding to each test tube .

10.Vortex each test tube for 2-3 seconds .

11. Inoculate test tubes at 37 ° C. and 200 RPM for 24 hours .

Results are determined by visual verification or O.D.
( a = 600 nm ) measurement of the growth or no growth
of bacteria .

Example 3

This study was conducted with N ,N '-di-n -octyl-4,13 - di
aza - 18 - crown - 6 (C , lariat ether ). A stock solution was pre
pared at a concentration of 20 mM in DMSO . A tetracycline
stock solution was prepared at a concentration of 1 mM in

Milli - Q H2O . An 80 uM solution of Cz lariat in media was
prepared by adding 8 uL of Cg lariat stock solution (20 mM )
to 2 mL media. Preparation of 60 uM , 40 uM , and 20 uM
solutions of Cg lariat , 6 UL , 4 uL , and 2 uL of Cg lariat stock

solution (20 mM) was added to 2 mL media respectively and
to make the volume of DMSO the same (0.4 vol- % with
respect to media ) appropriate volume of DMSO was added
(2 , 4 , and 6 of uL DMSO respectively ).

Example 4. Co - Administration of Antibiotics and
Lariat Ethers to E. coli . Cg Lariat ( MIC = 120 uM )
and Tetracycline Against E. coli DH5a (MIC = 10
60

UM )

Each concentration of Co- lariat was tested with different
concentrations of tetracycline ( from 6 uM to 0.25 uM) .
Tetracycline was dissolved in water . The volume of water
Minimal Inhibitory Concentration (MIC ) Procedure. The 65 added was between 12 to 0.5 uL . The volume of water added
steps used in the experimental determination of the mini was not constant but the volume of media was changed so
mum inhibitory concentration (MIC ) are recorded below.
that the total volume was kept constant at 2 mL .
Concentrations
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scale . The error bars represent the standard error. The lethal

Example 5. Procedure for the Assessment of
Potential Antibiotic Synergy

1. Steps 1-7 , described in the MIC procedure, shown in
Example 2 , were followed .

dose 50 (LD50 ) for each compound was calculated by using
the equation for a logarithmic regression curve . The R' value
for each curve was approximately 0.9 .

5

2. While the E. coli grew , the appropriate volume of com

pound was added to each test tube.
3. Antibiotics were added at the required volume of solution
to obtain the desired concentration in each test tube. The

1. A method of enhancing the antimicrobial activity of an
antibiotic, the method comprising administering the antibi
otic with a synthetic amphiphile to a bacterium that is

resistant to the antibiotic,

concentration of each compound was adjusted so that the
total volume of DMSO added to each test tube was 5 uL
(0.25 % by volume with respect to final volume i.e. 2000
UL . i.e. 2 mL ) .

10

5. Steps 10-12 from the MIC procedure , shown in Example

15

4. Each test tube was vortexed for 2-3 seconds .

What is claimed is :

wherein the synthetic amphiphile comprises the general
Formula 3 :
Formula 3

2 , were then executed .

Example 6. Determination of Toxicity of Lariat

R1 - N

N - R1

Ethers to HEK - 293 and E. coli Cells

20

Growth medium containing DMEM with high glucose
( ATCC ). 10% fetal bovine serum ( FBS : Sigma - Aldrich ) and
10 ug /mL of blasticidin ( Thermo -Fischer ) was prepared .
HEK 293 cells were thawed out from cryo -preserved
samples in 10 mL growth media , centrifuged at 500 rpm for 25
10 minutes to remove preservative. The cells were then
resuspended in fresh growth medium and cultured using a
T -75 flask ( Thermo - Fischer) at 37 ° C. and 5 % CO2 . Cells
were monitored for confluence and growth medium was
replaced every 48 h , until cells were placed onto a 96 - well 30

plate for toxicity studies .

After reaching 80-90 % confluence, cells were trypsinized
and suspended in media containing DMEM and 10 % FBS

(no antibiotics ). The cells were counted on a hemacytometer
and plated at a density of 20,000 cells per well in a 96 -well
plate and grown for 24 hours to reach 60-70% confluence .
DMSO stocks of C. , C3 , C10 , C11 and C14 diaza - 18 - crown - 6
lariat ethers were prepared at 200 mM and diluted 1:10 to get
working concentrations of 20 mM , 2 mM , and 0.2 mm . Each

wherein n is 1 and R , is a C8 - C12 linear alkyl,

wherein the synthetic amphiphile is administered at a
concentration of half or less of its minimum inhibitory
concentration (MIC ) against the antibiotic resistant
microbe as determined in the absence of the antibiotic,
wherein the antibiotic is tobramycin or tetracycline, and
wherein the antimicrobial activity of the antibiotic is
increased by at least 10 - fold by administration with the
synthetic amphiphile .
2. The method of claim 1 , wherein the antibiotic is also

35 administered
at a concentration
lower thethanantibiotic
its minimum
inhibitory concentration
(MIC ) against
resis

stock was further diluted 1 : 100 into DMEM supplemented 40

tant microbe as determined in the absence of the synthetic
amphiphile.
3. The method of claim 1 , wherein the synthetic amphi
phile
administered
an aggregate
of amphiphiles
or a
mixtureis of
amphiphilesaswith
a pharmaceutically
acceptable

with 10 % FBS to get final concentrations of 1 mM , 0.1 mM , solvent or solvent system .
0.01 mM ( 10 uM) and 0.001 mM ( 1 uM) . The original media
4. The method of claim 1 , wherein the antibiotic and the
was then removed from the cells and replaced with 200 uL synthetic
amphiphile are administered in a liposome .
media containing the desired concentration of compound.
5.
The
method
of claim 1 , wherein the antibiotic and the
Three wells were used for each concentration providing 45
experimental triplicates . As a positive control for growth , synthetic amphiphile have formed a salt .
6. The method of claim 1 , wherein the antibiotic and the
three wells containing cells were treated with DMEM synthetic
amphiphile are each administered in a salt form .
supplemented with 10 % FBS . For DMSO control, three
7.
The
method
of claim 1 , wherein the bacterium is in the
wells containing cells were treated with DMEM supple

mented with 10 % FBS and 0.5% DMSO . As anegative 50 family
, in, the familyinBacillaceae
in the
family Enterobacteriaceae
Staphylococcaceae
the ,family
control, wells without cells were treated with DMEM

supplemented with 10% FIBS and 0.5 % DMSO . The
96 -well plate was then returned to 37 ° C. and 5 % CO2 for

24 hours . After incubation . MTT assay ( Sigma -Aldrich ) was
performed according to manufacturer's protocol.The absorbance was measured at 570 nm and nonspecific absorbance

was corrected at 650 nm , using SpectraMax340 micro plate
reader.

or

Pseudomonadaceae .

8. The method of claim 1 , wherein the bacterium is E. coli .
9. The method of claim 8 , wherein the bacterium is a

55 tetracycline
tetracycline. resistant strain of E. coli and the antibiotic is

10. The method of claim 1 , wherein the synthetic amphi
phile is in a salt form by protonation or alkylation at

.
The experiment was performed in triplicate and the aver nitrogen
11.
The
of claim 1 , wherein the resistance of the
age of percent survival of three experiments was determined . 60 bacterium tomethod
the
antibiotic
is reversed .
The graph in FIG . 3 represents the percent survival with
increasing concentration of lariat ethers on a logarithmic

